These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24340099)

  • 21. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
    Kharat AA; Nelson R; Au T; Biskupiak J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
    Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
    Wu Q; Zhang P; Wang X; Zhang M; Liao W; Li Q
    Clin Ther; 2020 Nov; 42(11):2148-2158.e2. PubMed ID: 32981743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
    Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
    BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer.
    He J; Wen F; Yin X; Zhang P; Du Z; He X; Zhou Y; Tang R; Li M; Li Q
    Anticancer Drugs; 2013 Aug; 24(7):754-8. PubMed ID: 23629479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
    Shiroiwa T; Fukuda T; Tsutani K
    Br J Cancer; 2009 Jul; 101(1):12-8. PubMed ID: 19491895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.
    Li S; Peng L; Tan C; Zeng X; Wan X; Luo X; Yi L; Li J
    PLoS One; 2020; 15(5):e0232240. PubMed ID: 32379763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
    Zhang Q; Qian Y; Yin Y
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
    Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients].
    Jiang ZM; Wei Y; Zhang YD; Zhou SW; Yang Q; Xie DR
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):534-7. PubMed ID: 23801205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.